These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29305017)

  • 1. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
    Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
    Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational study.
    Ota Y; Obata Y; Takazono T; Tashiro M; Wakamura T; Takahashi A; Shiozawa Y; Miyazaki T; Nishino T; Izumikawa K
    BMC Nephrol; 2021 Jun; 22(1):240. PubMed ID: 34193064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
    Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
    Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation.
    Yasu T; Konuma T; Oiwa-Monna M; Kato S; Tanoue S; Isobe M; Mizusawa M; Kuroda S; Takahashi S; Tojo A
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.
    Andrew EC; Curtis N; Coghlan B; Cranswick N; Gwee A
    Br J Clin Pharmacol; 2018 May; 84(5):1006-1012. PubMed ID: 29352486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases.
    Ueda S; Miyamoto S; Kaida K; Chizuka A; Kojima R; Takano J; Ogasawara T; Miyamoto K; Miyakoshi S; Kanda Y
    J Infect Chemother; 2016 May; 22(5):287-91. PubMed ID: 26908230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between the hypokalaemia index based on area over the serum potassium concentration curve and occurrence of acute kidney injury in patients administered liposomal amphotericin B.
    Ueda T; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Takubo S; Iijima K; Uchino M; Horio Y; Kuwahara R; Kimura T; Murakami Y; Nozaki Y; Nakama S; Miyazaki Y; Takesue Y
    Mycoses; 2024 Jul; 67(7):e13771. PubMed ID: 39031945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity.
    Yokota T; Yoshikawa N; Arimori K; Ikeda R
    Pharmazie; 2020 Nov; 75(11):599-601. PubMed ID: 33239137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
    Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
    J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.
    Stanzani M; Vianelli N; Cavo M; Maritati A; Morotti M; Lewis RE
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.
    Azoulay E; Timsit JF; Lautrette A; Legriel S; Max A; Ruckly S; Misset B; Cohen Y; Wolff M
    PLoS One; 2017; 12(5):e0177093. PubMed ID: 28531175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy.
    Burnett YJ; Spec A; Ahmed MM; Powderly WG; Hamad Y
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33846129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
    Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
    Falci DR; da Rosa FB; Pasqualotto AC
    Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.
    Della Pepa R; Picardi M; Sorà F; Stamouli M; Busca A; Candoni A; Delia M; Fanci R; Perriello V; Zancanella M; Nosari A; Salutari P; Marchesi F; Pane F; Pagano L;
    Support Care Cancer; 2016 Sep; 24(9):3839-45. PubMed ID: 27075673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.
    Seibel NL; Shad AT; Bekersky I; Groll AH; Gonzalez C; Wood LV; Jarosinski P; Buell D; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of renal effects of liposomal amphotericin B in children with malignancies with KDIGO and RIFLE criteria.
    Devrim F; Çağlar İ; Acar SO; Akkuş Ş; Dinçel N; Yılmaz E; Tahta N; Demirağ B; Karapınar TH; Gözmen S; Oymak Y; Vergin C; Bayram N; Devrim İ
    Nephrol Ther; 2021 Dec; 17(7):507-511. PubMed ID: 34535406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan.
    Takazono T; Tashiro M; Ota Y; Obata Y; Wakamura T; Miyazaki T; Nishino T; Izumikawa K
    Sci Rep; 2020 Sep; 10(1):15033. PubMed ID: 32929112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.